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Introduction
The five mAChRs are prototypical Family A members of the G protein-coupled receptor (GPCR) superfamily and are widespread throughout the central nervous system and periphery Hulme et al., 1990; Wess et al., 2007) . Based on anatomical, pharmacological, and preclinical animal model studies, the M 1 mAChR subtype has long been considered a potential therapeutic target for the treatment of cognitive deficits associated with disorders such as Alzheimer's disease and schizophrenia (Langmead et al., 2008b) .
Importantly, human clinical data derived from trials utilizing the M 1 /M 4 mAChR-preferring mAChR agonist, xanomeline, have also provided evidence for cognitive improvement (Bodick et al., 1997; Shekhar et al., 2008) . However, the development of truly subtypeselective mAChR agonists has been hampered by the very high degree of sequence homology within the orthosteric (acetylcholine-binding) site across all five mAChRs (Hulme et al., 1990) .
It is now well established that mAChRs also possess topographically distinct allosteric binding sites that may offer a novel avenue towards attaining greater receptor subtype selectivity (Conn et al., 2009) . Although early studies in this area focused on allosteric modulators, such as gallamine and C 7 /3-phth, which regulated the actions of orthosteric ligands while lacking any appreciable intrinsic efficacy of their own (Gregory et al., 2007) , recent progress has been made in identifying novel selective agonists that also display pharmacological characteristics suggestive of an allosteric mode of action. The best studied agonist in this regard is AC-42 ( Fig. 1) , which possesses significant functional selectivity for MOL # 64345 as Y 106 A, Y 381 A and N 382 A (residues 3.33, 6.51 and 6.52, respectively, using the Ballesteros and Weinstein, (1995) convention), which have profound inhibitory effects on the binding and/or function of the prototypical non-selective orthosteric agonist, carbachol (Spalding et al., 2006; Spalding et al., 2002) . However, additional mutational analysis of key residues in transmembrane domain (TM) 3 of the rat M 1 mAChR identified L 102 A (3.29) as a mutation that inhibited the function of both carbachol and AC-42, and W 101 A (3.28) as a mutation that profoundly increased the function of AC-42, while inhibiting that of carbachol (Spalding et al., 2006) . Thus, an interesting picture is emerging that suggests that novel agonists, such as AC-42, although clearly binding in a different mode to prototypical orthosteric agonists can still display sensitivity to some receptor epitopes commonly associated with the orthosteric binding pocket. One possible explanation for such findings may be that the novel agonists are "bitopic" ligands, being able to interact with regions in both orthosteric and allosteric sites, as has been demonstrated recently for the partial agonist, 4-I-[3-chlorophenyl]carbamoyloxy)-2-butynyltrimethylammnonium chloride , at the M 2 mAChR (Valant et al., 2008 ).
More recently, we have described a new agonist, 77-LH-28-1 (Fig. 1 ), which is a structural analogue of AC-42 that also displays functional selectivity for the M 1 mAChR over other subtypes (Langmead et al., 2008a; May et al., 2007) . 77-LH-28-1 is bioavailable, brainpenetrant and, importantly, displays higher efficacy than AC-42 when tested at native M 1 mAChRs (Langmead et al., 2008a) . At the M 2 mAChR, 77-LH-28-1 can act as an allosteric modulator of [ 3 H]NMS dissociation kinetics (May et al., 2007) , and a very recent study at the M 1 mAChR (Lebon et al., 2009 ) suggested a novel binding mode for both 77-LH-28-1 and MOL # 64345 HEPES buffer (20 mM HEPES, 100 mM NaCl, 10 mM MgCl 2 , pH 7.4) at 37°C for 1 hr prior to termination of the assay by rapid filtration onto GF/B grade filter paper using a Brandel harvester, followed by 3 x 2 ml washes with ice-cold NaCl (0.9%). Nonspecific binding was defined in the presence of 10 μM atropine and radioactivity was determined by liquid scintillation counting. For inhibition binding assays, membranes were incubated in HEPES buffer containing increasing concentrations of the allosteric modulator, C 7 /3-phth, or either of the novel agonists, 77-LH-28-1 or AC-42, for 1 hr at 37°C in the presence of a [ 3 H]NMS concentration approx. equal to its equilibrium dissociation constant, unless specified otherwise in the Results. Non-specific binding, reaction termination and radioactivity determination were as described above.
For binding assays performed on intact U2OS cells, cells were first transduced with various amounts of plaque forming units (0.5 or 1.25 pfu/ml as indicated in Tables 1-3) Non-specific binding was defined using 10 μ M atropine. Incubation was terminated by rapid filtration through Whatman GF/C filters using Brandel cell harvester (Gaithersburg, MD). All other details were as described above.
This article has not been copyedited and formatted. The final version may differ from this version. , 1996; Lazareno and Birdsall, 1995) ; this was the case in our current study. Termination of the reaction and determination of radioactivity were performed as described above.
U2OS cell intracellular calcium elevation assays
U2OS cells were transduced as described above and plated at a density of 50,000 cells/well in 96-well clear flat bottom plate. After 22 hr at 37°C, 5% CO 2 , the cells were washed twice with Ca ++ assay buffer and loaded with Ca ++ assay buffer containing 10 μ M Fluo-4 and incubated in dark. The cells were then washed twice with Ca ++ buffer to remove excess Fluo-4. The calcium elevation in response to addition increasing concentrations of ligand was measured for 3 min at 1.5 sec intervals using a Flexstation (Molecular Devices). For functional interaction studies, cells were incubated at 37°C with varying concentrations of ACh in the absence and presence of different concentrations of a second compound (see Results), which was added 60 sec prior to the addition of ACh for a further 120 sec. Calcium elevation was measured using Flexstation at an interval of 1.5 sec for a total of 195 sec.
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U2OS cell extracellular signal regulated kinase 1/2 phosphorylation (pERK1/2) assays
Initial ERK1/2 phosphorylation time-course experiments were performed to determine the time at which ERK1/2 phosphorylation was maximal following stimulation by each agonist.
Cells were seeded into transparent 96-well plates at 40,000 cells per well and grown overnight or until confluent. Cells were then washed twice with PBS and incubated in serum-free DMEM at 37 o C for at least 4 hr to allow FBS-stimulated phosphorylated ERK1/2 (pERK1/2) levels to subside. Cells were stimulated with agonist using a staggered addition approach.
For subsequent agonist-stimulated concentration-response experiments, cells were incubated at 37°C with each agonist for the 8 min required to achieve peak response. For all experiments, 10% FBS was used as a positive control, whilst vehicle controls were also performed. The reaction was terminated by removal of drugs and lysis of cells with 100 μl SureFire™ lysis buffer (as provided by the manufacturer). The lysates were agitated for 1-2 min and were diluted at a ratio of 4:1 v/v lysate:Surefire™ activation buffer in a total volume of 50 μl. Under low light conditions a 1:240 v/v dilution of AlphaScreen™ beads: Surefire™ reaction buffer was prepared and this was mixed with the activated lysate mixture in a ratio of 6:5 v/v, respectively, in a 384-well opaque Optiplate™. Plates were incubated in the dark at 37°C for 1.5 hr before the fluorescence signal was measured using a Fusion-α™ plate reader (PerkinElmer) using standard AlphaScreen™ settings.
Construction of an M 1 mAChR model
The initial model of the TM domain of the human M 1 mAChR was constructed by homology with the published X-ray crystal structure of β 2 adrenergic receptor 2RH1 (Cherezov et al., 2007) . Alignment between the M 1 mAChR sequence and β 2 receptor was based on the "classical" motifs found in each TM region, such as the asparagine in TM1, the aspartate in This article has not been copyedited and formatted. The final version may differ from this version.
TM2, the "DRY" motif of TM3, the tryptophan in TM4, and the conserved prolines in TM5, TM6 and TM7. This alignment was used, with the standard homology modeling tools in the Quanta program (Accelerys Software, San Diego) to construct the seven helical bundle domain of the M 1 mAChR. The extracellular loop regions were subsequently added using a procedure developed in-house at GlaxoSmithKline, which makes use of a combined distance geometry sampling and molecular dynamics simulation (Blaney et al., 2001) . The sidechains of this model were then refined using the Karplus standard rotamer library (Dunbrack and Karplus, 1993 ). The final model was optimized fully (500 steps of Steepest Descent (SD)
followed by 5000 steps of Adopted Basis Newton Raphson (ABNR)) using the CHARMm force field. Helical distance constraints between the i th and i+4 th residues (except proline) within a range of 1.8Å-2.5Å, were used to maintain the backbone hydrogen bonds of the helix bundles.
Ligand docking studies
AC-42 and 77-LH-28-1 were docked into the receptor model manually using a variety of low energy starting conformations. Adjustments of the receptor protein sidechains were made where necessary, always ensuring that these sidechains were only in allowed rotameric states (Dunbrack and Karplus, 1993) . Once again, full optimization of the receptor-ligand complexes was performed using CHARMm, the only constraints used being those that maintained the hydrogen bonding pattern of the helical bundle. This procedure allows full relaxation of both the ligand and the whole protein, something that is not possible with automated docking procedures. Although numerous binding orientations were found to be possible, one docked binding mode that accommodated both novel agonists satisfied much of the site-directed mutagenesis data generated.
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This article has not been copyedited and formatted. The final version may differ from this version. Dissociation kinetic data all followed a monoexponential decay. Thus, the following equation was fitted to these data:
where t denotes incubation time, B t denotes specific radioligand binding at time t, B 0 denotes the specific radioligand binding at time at equilibrium (time = 0) and k off represents the observed radioligand dissociation rate constant. For the two-point dissociation experiments, where the effects of a range of concentrations of allosteric modulators were investigated, individual k off values determined in the presence of modulator were normalized to the control k off value (absence of modulator) and then plotted as a function of modulator concentration.
The following three-parameter logistic equation was fitted to concentration-response data generated from the functional U2OS cell-based assays:
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where E is response, E max and Bottom are the top and bottom asymptotes of the curve, respectively, [A] is the agonist concentration and pEC 50 is the negative logarithm of the agonist concentration that gives a response halfway between E max and Bottom. Where appropriate, the following form of an operational model of agonism (Black and Leff, 1983) was also fitted to agonist data:
where E m is the maximal possible response of the system (not the agonist), Basal is the basal level of response in the absence of agonist, K A denotes the functional equilibrium dissociation constant of the agonist (A), τ is an index of the coupling efficiency (efficacy) of the agonist and is defined as R T /K E where R T is the total concentration (B max ) of receptors and K E is the concentration of agonist-receptor complex that yields half the maximum system response (E m ). Throughout this study, all references to the term "efficacy" specifically relate to the property quantified by τ. To define the E m and τ for each mutant and assay, the K A for each agonist was constrained to equal the K A value derived from radioligand binding assays (see
Results)
in the nonlinear regression procedure. In addition, because the τ parameter can be influenced by variations in the expression level of various receptor constructs, the values reported in this study have been normalized according to the following ratio: τ corrected (τ C ) = τ estimated × (B max-mutant /B max-wildtype ) (see Gregory et al., 2010) .
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where s represents the Schild slope for the antagonist, and pA 2 represents the negative logarithm of the molar concentration of antagonist that makes it necessary to double the concentration of agonist needed to elicit the original submaximal response obtained in the absence of antagonist; all other parameters are as defined above in equation 5. The following operational model for the competitive interaction between an orthosteric full and partial agonist, as derived previously by (Leff et al., 1993) , was also fitted to the interaction data between ACh and 77-LH-28-1:
where the parameters are as described above for equations 6 and 7.
All parametric measures of potency, affinity, operational efficacy and cooperativity were estimated as logarithms (Christopoulos, 1998) . In all instances, models were fitted to pooled datasets. Statistical comparisons between parameters were performed using Student t-test or F-test, where appropriate, with p < 0.05 taken as indicating significance.
This article has not been copyedited and formatted. The final version may differ from this version. Figure   2A ). In order to reveal any potential allosteric mechanism of action, the same experiment was performed using 2 nM [ control, although not to the same extent as observed with C 7 /3-phth (P < 0.05; one-way ANOVA followed by Dunnett's post test; Figure 3A ). These effects clearly show that both AC-42 and 77-LH-28-1 are able to interact allosterically with the [ 3 H]NMS-occupied receptor.
We then used a "two-point kinetic" experimental paradigm (Kostenis and Mohr, 1996) , to determine the concentration-dependence of the effect of C 7 /3-phth on However, it was possible to probe the interaction between C 7 /3-phth and 77-LH-28-1 using this experimental design. As shown in Figure 3B , 77-LH-28-1 (300 μM) produced a significant 6-fold rightward shift in the concentration-response curve of C 7 /3-phth to inhibit shares some of its binding site with that of the prototypical mAChR allosteric modulator, 
Effects of key M 1 mAChR mutations on agonist pharmacology
The preceding studies indicated that the novel agonists display pharmacology that is consistent with both orthosteric and allosteric modes of action, depending on the experimental design. It is possible that such compounds recognize epitopes in both these regions of the receptor, and adopt more than one binding pose depending on whether the orthosteric site is occupied by another ligand or not. To further probe these interactions at the molecular level, (Spalding et al., 2002; Sur et al., 2003; Ward et al., 1999) . W 101 in TM3 of the M 1 mAChR has previously been shown to be part of a 'second-shell' of residues that surround the orthosteric binding site (Hulme et al., 2003) , and W 101 A mutation markedly increases the potency of This article has not been copyedited and formatted. The final version may differ from this version. Conversely, this mutation resulted in significant increases in the affinity of AC-42 and 77-LH-28-1 (Table 1) , in agreement with previous binding studies ( Lebon et al., 2009 ).
Interestingly, this mutation did not alter the efficacies of ACh and pilocarpine ( To further verify this novel observation, the activity of all four agonists was examined at both the wild-type and F 77 I constructs in a second signaling assay, that of ERK1/2 phosphorylation. All agonists displayed Logτ c values somewhat lower than those observed in the Ca ++ assay (Table 3 ; Fig. 7) , suggesting that the receptor coupling efficiency in the pERK1/2 assay is lower. In agreement with the previous dataset, mutation of F 77 did not alter the efficacy of ACh or pilocarpine, but reduced the efficacy of 77-LH-28-1 and abolished the agonist activity of AC-42 (Table 3 ; Fig. 7 ). Thus the selective modulation of the efficacy of the novel agonists by F 77 I was not restricted to a single pathway but observed for both Ca ++ elevation and ERK1/2 phosphorylation.
Discussion
The past decade has witnessed a virtual renaissance in the pharmacology of mAChR agonists, spearheaded by the discovery of compounds such as AC-42, which preferentially activate the muscarinic M 1 mAChR subtype (Langmead et al., 2006; Spalding et al., 2002) . Importantly, a common mechanism invoked to explain the functional selectivity of these agonists has been one involving the possibility that they are allosteric (Jones et al., 2008; Langmead et al., 2006; Spalding et al., 2006; Sur et al., 2003) . Our current findings suggest that these novel agonists indeed adopt different poses within the M 1 mAChR relative to prototypical orthosteric agonists such as ACh, but that they are unlikely to result in a purely allosteric mode of action.
It is of note that in previous studies (Langmead et al., 2006; Lebon et al., 2009) , and in our current study, the interactions between 77-LH-28-1 or AC-42 with orthosteric antagonists were consistently characterized by very high degrees of negative cooperativity (Log α values ≥ -2), as determined by application of an allosteric ternary complex model to the data. Such highly negative allosteric interactions are virtually indistinguishable from a competitive interaction at equilibrium. This is in contrast to prototypical allosteric modulators, such as C 7 /3-phth, which can be shown to interact via a purely allosteric mode in both equilibrium ( Figure 2B ) and kinetic (Figure 3 ) studies. The ability of ligands such as C 7 /3-phth and 77-LH-28-1 to alter the dissociation rate of an orthosteric ligand is a key indicator of an allosteric interaction, but it should be noted that this type of assay monitors interactions on a receptor that has been pre-labeled with an orthosteric radioligand; dissociation kinetic experiments can reveal whether a ligand is able to adopt an allosteric binding pose, but cannot be used to conclude that this pose is relevant to a receptor that does not have an orthosteric ligand present. Indeed, functional interaction studies utilizing 77-LH-28-1 were in agreement with the equilibrium binding studies in that the interaction between this agent and the orthosteric agonist, ACh, were consistent with a simple competitive mechanism (Figure 5 ), or very high This article has not been copyedited and formatted. The final version may differ from this version. negative cooperativity. This finding also complements previous data that showed the functional interaction between 77-LH-28-1 and scopolamine or pirenzepine were indistinguishable from simple competition (Langmead et al., 2008a) . Although our finding of apparent competition between 77-LH-28-1 and C 7 /3-phth on the [
H]NMS-occupied receptor
indicates that the novel agonist has the capacity to recognize epitopes that constitute the prototypical allosteric binding site on the M 1 mAChR, the log. affinity of the agonist for the occupied receptor (approx. 4.3) is markedly lower than its log. affinity for the free receptor (approx. 6.3). Given that the novel agonists have a much lower affinity for the allosteric site on the M 1 mAChR when the receptor is occupied by orthosteric ligand, it is unlikely that their purely allosteric properties will play a prominent role in their pharmacological effects at concentrations that are physiologically relevant.
Overall, the profile of behaviors exhibited by the novel agonists are qualitatively and quantitatively similar to that displayed by the mAChR partial agonist, McN-A-343, whose mechanism of action was the subject of debate in the literature (Birdsall et al., 1983; Christopoulos and Mitchelson, 1997; May et al., 2007) . More recently, radioligand binding, functional and mutagenesis studies utilizing fragments of McN-A-343 revealed it to be a 'bitopic' ligand, namely, a hybrid molecule capable of interacting concomitantly with the receptor via both orthosteric and allosteric sites (Valant et al., 2008) . This is a mode of interaction that is distinct from a 'pure' allosteric mode. Due to its recognition of epitopes within the orthosteric pocket, McN-A-343 appears competitive in equilibrium binding or functional assays, but utilizes regions of the allosteric site to derive functional selectivity;
when the orthosteric site is pre-bound with radioligand, it adopts a second, purely allosteric binding mode, with much lower affinity. Given the parallels in the pharmacology, this may be a likely mechanism by which 77-LH-28-1 interacts with the unoccupied muscarinic M 1 mAChR, and one we have proposed for this agonist at the M 2 mAChR (Gregory et al., 2010) .
This article has not been copyedited and formatted. The final version may differ from this version. Our modeling and ligand docking also support the notion that 77-LH-28-1 and AC-42 are bitopic ligands (Valant et al., 2008; Valant et al., 2009 ). Both agonists have basic centres that are likely to interact with D 105 in the orthosteric binding site; previous mutational data support the requirement of this residue for receptor activation by these agonists (Lebon et al., 2009 ).
However, the benzoyl aromatic group of 77-LH-28-1 is predicted to occupy space between TM domains 2, 3 and 7, close to the extracellular loops. Interestingly, W 101 is thought to form the base of the binding site for the prototypical allosteric modulators such as C 7 /3-phth (Matsui et al., 1995) . This binding mode would explain the observation that 77-LH-28-1 appears to compete (at least in part) for the same binding site as C 7 /3-phth ( Figure 3B ). It is likely that interactions in this region are responsible for the observed allosteric effects of 77-LH-28-1 when the receptor is pre-bound with The residues chosen for mutagenesis, W 101 , Y 381 and F 77 , also proved useful in identifying patterns of behavior that can be used to differentiate prototypical orthosteric agonists from novel selective agonists (including putative bitopic agonists). The first two residues were selected as their mutation has been shown to have divergent effects on orthosteric and putatively allosteric agonists (Lebon et al., 2009; Spalding et al., 2006; Spalding et al., 2002) , AC-42 and related compounds (Spalding et al., 2006) . The same mutation significantly reduced ACh and pilocarpine affinity but significantly enhanced AC-42 and 77-LH-28-1 affinity (Table 1) ; there was no change in agonist efficacy with the exception of a reduction in the Logτ c value for AC-42 (Table 2 ). These data suggest that W 101 primarily plays a role in the binding of 77-LH-28-1, probably by 'flipping out' to accommodate the ligand; therefore the absence of the side chain reduces the free energy required for ligand binding.
Mutation of Y 381 A significantly reduced the affinity of pilocarpine and ACh for the M 1 receptor (Table 1) , consistent with a role in the orthosteric binding site (Ward et al., 1999) .
Interestingly, this mutation moderately increased the affinity of AC-42 and 77-LH-28-1 (Table 1) but significantly reduced the efficacy of all agonists tested (Table 2) At first sight, the role of F 77 appears to be difficult to resolve based on the receptor model, as the residue faces away from the proposed ligand binding site (Figure 8 ). However, mutation of this residue has a clear effect to selectively reduce the efficacy of AC-42 and 77-LH-28-1 (Tables 2 and 3 ). On this basis we postulate that the aromatic side chain of F 77 plays a role to stabilise the 'flipped out' gauche state of W 101 via a π -π stacking interaction between the aromatic rings; this selectively enhances the function of AC-42 and 77-LH-28-1 whilst leaving pilocarpine and ACh unaffected. Therefore removal of the aromatic ring prevents this stabilisation and reduces the ability of 77-LH-28-1 to mediate receptor activation once bound.
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